CLENE INC (CLNN)

Company Profile

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. The company is headquartered in Salt Lake City, Utah and currently employs 75 full-time employees. The company went IPO on 2018-08-27. The firm is focused on treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. Its drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. Its other products include CNM-ZnAg and CNM-AgZn17. CNM-ZnAg is a spectrum antiviral, antibacterial agent comprised of zinc and silver ions under development to treat infectious disease and to provide immune support for symptom resolution. CNM-AgZn17 is a gel polymer suspension of zinc and silver under development for treatment of infectious diseases and to support wound healing.

Company Info

CLENE INC

6550 South Millrock Drive, Suite G50

Salt Lake City UTAH 84121

P: 18016769695

CEO: Robert Etherington

Employees: 75

Website: https://clene.com/